CAMP4 Therapeutics (NASDAQ:CAMP) Stock Rating Upgraded by Zacks Research

CAMP4 Therapeutics (NASDAQ:CAMP) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Other analysts have also recently issued reports about the stock. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Piper Sandler reaffirmed an “overweight” rating and set a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday. Finally, UBS Group set a $15.00 price target on CAMP4 Therapeutics in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CAMP4 Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $9.56.

CAMP4 Therapeutics Trading Down 2.0%

Shares of NASDAQ CAMP opened at $4.90 on Monday. CAMP4 Therapeutics has a twelve month low of $1.41 and a twelve month high of $7.75. The company has a market capitalization of $307.48 million, a price-to-earnings ratio of -2.11 and a beta of 0.22. The firm has a 50-day moving average of $4.10 and a two-hundred day moving average of $4.32.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The business had revenue of $1.78 million during the quarter. As a group, research analysts predict that CAMP4 Therapeutics will post -0.66 earnings per share for the current year.

Insider Buying and Selling

In other CAMP4 Therapeutics news, Director Richard A. Young bought 16,378 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $1.65 per share, with a total value of $27,023.70. Following the completion of the transaction, the director directly owned 186,388 shares of the company’s stock, valued at approximately $307,540.20. The trade was a 9.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 36,031 shares of company stock valued at $59,451 in the last 90 days. Corporate insiders own 21.69% of the company’s stock.

Institutional Investors Weigh In On CAMP4 Therapeutics

Large investors have recently bought and sold shares of the business. Bridgeway Capital Management LLC acquired a new position in CAMP4 Therapeutics during the second quarter worth $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth about $61,000. Jefferies Financial Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth about $70,000. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth about $78,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.